Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Allopurinol-Induced Leukocytoclastic Vasculitis With Systemic Inflammatory Response: A Case Report From Azerbaijan.

Created on 04 Sep 2026

Authors

Divya Ravikumar, Godly Silven, Hamida Salimzade

Published in

Cureus. Volume 18. Issue 8. Pages e113944. Epub Aug 04, 2026.

Abstract

Allopurinol is a commonly prescribed xanthine oxidase inhibitor used in the management of hyperuricemia and gout. Although generally well tolerated, it is associated with rare but potentially life-threatening hypersensitivity reactions, including allopurinol-induced vasculitis. We present the case of a 66-year-old woman who developed an acute cutaneous eruption 14 days after initiating allopurinol 100 mg daily for the management of recurrent gout. She subsequently developed systemic inflammatory manifestations, hepatic involvement, hematologic abnormalities, and immunologic activation consistent with drug-induced vasculitis following exposure to allopurinol. Laboratory findings demonstrated marked elevation of inflammatory markers, liver enzymes, immunoglobulin E levels, and evolving hematologic changes, including eosinophilia followed by lymphocytosis. The patient required plasmapheresis as part of management. This case highlights the importance of early recognition of drug-induced vasculitis and the need for prompt intervention to prevent progression to severe systemic complications.

PMID:
42694996
Bibliographic data and abstract were imported from PubMed on 04 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement